Evotec and BMS increase stakes in Oxford-based Dark Blue Therapeutics
Published
Dark Blue Therapeutics is an Oxford-based biotechnology company founded in 2020. The firm discovers and develops precision oncology therapies, focusing on medicines that exploit cancer vulnerabilities such as MLLT1/3 degraders for acute myeloid leukemia and solid tumors.
Recent filings show that Evotec International GmbH and BMS Strategic Portfolio Investments Holdings, Inc have both increased their holdings in the company. Evotec International GmbH added 9,963,013 shares to its position, a 62 percent increase that brings its total holding to 25,963,013 shares. This total includes 23,088,013 Series A2 shares, 2,500,000 Series A shares, and 375,000 Ordinary shares.
BMS Strategic Portfolio Investments Holdings, Inc increased its stake by 64 percent, adding 9,950,547 shares. The investor now holds 25,575,547 shares in total, consisting of 23,075,547 Series A2 shares and 2,500,000 Series A shares. The simultaneous increase in holdings by these two major investors may signal a recent funding round.
Other existing shareholders remaining on the cap table include Oxford Science Enterprises PLC, which holds 5,831,250 shares, and the University of Oxford, which maintains a holding of 1,593,750 shares. These changes were recorded in a confirmation statement covering the period up to 3 June 2024.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Increased | EVOTEC INTERNATIONAL GMBH | 25,963,013 | +62% | SERIES A2 23,088,013 SERIES A 2,500,000 ORDINARY 375,000 |
| Increased | BMS STRATEGIC PORTFOLIO INVESTMENTS HOLDINGS, INC | 25,575,547 | +64% | SERIES A2 23,075,547 SERIES A 2,500,000 |
Current shareholders (4)
| Shareholder | Total shares | Share classes |
|---|---|---|
| EVOTEC INTERNATIONAL GMBH | 25,963,013 | ORDINARY 375,000 SERIES A 2,500,000 SERIES A2 23,088,013 |
| BMS STRATEGIC PORTFOLIO INVESTMENTS HOLDINGS, INC | 25,575,547 | SERIES A 2,500,000 SERIES A2 23,075,547 |
| OXFORD SCIENCE ENTERPRISES PLC | 5,831,250 | ORDINARY 2,831,250 SERIES A 3,000,000 |
| THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | 1,593,750 | ORDINARY 1,593,750 |
Contact the editorial team at [email protected]